Print

Purpose

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Age ≥ 18 years 2. Scalp biopsy consistent with LPP 3. Active and symptomatic LPP at screening and baseline- 4. Weight > 40 kg to < 130 kg with BMI ≤ 45 kg/m2

Exclusion Criteria

  1. History of: Lymphoproliferative disorder; Active malignancy; History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid cancer). 2. High risk of thrombosis or cardiovascular disease 3. High risk of herpes zoster 4. Active or recent infection

Study Design

Phase
Phase 2/Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Triple (Participant, Care Provider, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Brepocitinib Dose Level 1
  • Drug: Oral Brepocitinib
    Oral
Placebo Comparator
Placebo
  • Drug: Placebo
    Oral

Recruiting Locations

Clinical Trial Site
Birmingham, Alabama 35244

Clinical Trial Site
Phoenix, Arizona 85006

Clinical Trial Site
Scottsdale, Arizona 85259

Clinical Trial Site
Irvine, California 92617

Clinical Trial Site
Oakland, California 94611

Clinical Trial Site
Sacramento, California 95823

Clinical Trial Site
San Francisco, California 94115

Clinical Trial Site
Denver, Colorado 80237

Clinical Trial Site
Farmington, Connecticut 06032

Clinical Trial Site
New Haven, Connecticut 06519

Clinical Trial Site
Miami, Florida 33136

Clinical Trial Site
Chicago, Illinois 60611

Clinical Trial Site
Skokie, Illinois 60077

Clinical Trial Site
Clarksville, Indiana 47129

Clinical Trial Site
Indianapolis, Indiana 46250

Clinical Trial Site
Leawood, Kansas 66211

Clinical Trial Site
Louisville, Kentucky 40241

Clinical Trial Site
Boston, Massachusetts 02115

Clinical Trial Site
Burlington, Massachusetts 01805

Clinical Trial Site
Ann Arbor, Michigan 48103

Clinical Trial Site
Ann Arbor, Michigan 48109

Clinical Trial Site
Medina, Minnesota 55340

Clinical Trial Site
Minneapolis, Minnesota 55455

Clinical Trial Site
Kansas City, Missouri 66103

Clinical Trial Site
Lee's Summit, Missouri 64064

Clinical Trial Site
Lebanon, New Hampshire 03766

Clinical Trial Site
New Hyde Park, New York 11042

Clinical Trial Site
New York, New York 10451

Clinical Trial Site
Durham, North Carolina 27713

Clinical Trial Site
Cleveland, Ohio 44195

Clinical Trial Site
Columbus, Ohio 43213

Clinical Trial Site
Medina, Ohio 44256

Clinical Trial Site
Portland, Oregon 97210

Clinical Trial Site
Philadelphia, Pennsylvania 19104

Clinical Trial Site
Charleston, South Carolina 29425

Clinical Trial Site
Murfreesboro, Tennessee 37128

Clinical Trial Site
Smyrna, Tennessee 37167

Clinical Trial Site
Austin, Texas 78613

Clinical Trial Site
Austin, Texas 78660

Clinical Trial Site
Cedar Park, Texas 78613

Clinical Trial Site
Prosper, Texas 75078

Clinical Trial Site
Tyler, Texas 75703

Clinical Trial Site
Murray, Utah 84107

Clinical Trial Site
Norfolk, Virginia 23502

Clinical Trial Site
Richmond, Virginia 23235

Clinical Trial Site
Roanoke, Virginia 24016

Clinical Trial Site
Mill Creek, Washington 98012

More Details

Status
Recruiting
Sponsor
Priovant Therapeutics, Inc.

Study Contact

Clinical Trial Administrator
(212) 634-9743
clinicaltrials@priovant.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.